RAGE and Its Ligands in Melanoma

The document discussed the role of the receptor for advanced glycation end products (RAGE) and its ligands in melanoma progression, identifying RAGE as a potential therapeutic target due to its involvement in cell proliferation, migration, and inflammation. RAGE overexpression in melanoma cells led to decreased proliferation but increased migration and invasion, with significant variations in expression levels across samples. S100 proteins, particularly S100B, S100A2, S100A4, and S100A6, were linked to cancer progression, interacting with the tumor suppressor p53 and affecting its function. S100B served as a prognostic marker for stage IV melanoma. Advanced Glycation End-products (AGEs) and High Mobility Group Box 1 protein (HMGB1) were also implicated in promoting metastasis and angiogenesis through RAGE signaling. Despite the potential of targeting RAGE/ligand interactions with inhibitors like soluble RAGE (sRAGE) and anti-RAGE antibodies, the efficacy in melanoma remained uncertain due to variable RAGE levels, necessitating further studies.